Effect of Probiotics on Helicobacter Pylori Eradication

Helicobacter Pylori Eradication Clinical Trial

Official title:

Clinical Study on Bifidobacterium Quadruple Live Bacteria Tablets (Si Lian Kang) Reducing the Incidence Rate of Adverse Reactions in Helicobacter Pylori Quadruple Eradication Therapy and on the Effects of Gastrointestinal Flora

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT04034641
• Other study ID #: HangzhouGrand
• Status: Recruiting
• Phase: Phase 4
• Start date: June 17, 2019
• Est. completion date: December 31, 2021

Study information

• Verified date: July 2019
• Source: Hangzhou Grand Biologic Pharmaceutical, Inc.
• Contact: Lu Zhang, master
• Phone: +8615901365519
• Email: zhanglu[@]hzydsw.cn
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this clinical trial is to evaluate the clinical efficacy of Bifidobacterium quadruple live bacteria tablets (Si Lian Kang) on reducing the incidence rate of adverse reactions of Helicobacter pylori quadruple eradication therapy and its influence on gastrointestinal flora.

Description:

Bismuth agent quadruple therapy (including bismuth agent and proton pump inhibitor combined with two antibiotics) is the first-line strategy to eradicate Helicobacter pylori in China. However, it may cause a series of adverse reactions, such as nausea, diarrhea, abdominal pain, constipation, and abnormal taste, etc., which leads to a decrease in patient compliance, thereby affecting the treatment effect. Many studies have found that adding probiotics to traditional Helicobacter pylori eradication therapies increase eradication rates and reduce the side effects of the treatment. Bifidobacterium tetrad live bacteria tablet is a compound microecological preparation composed of bifidobacterium infantis, lactobacillus acidophilus, enterococcus faecalis and bacillus cereus. This study aims to observe the clinical efficacy of Bifidobacterium quadruple live bacteria tablets (Si Lian Kang) on reducing the incidence rate of adverse reactions in Helicobacter pylori quadruple eradication therapy and on the effects of gastrointestinal flora.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 238
• Est. completion date: December 31, 2021
• Est. primary completion date: December 31, 2020
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 65 Years

Eligibility

Inclusion Criteria:

1. Voluntarily signing the informed consent form;

2. Aged 18-65 years old(including 65), male or female;

3. Patients aged 35-65 years old(including 35) with positive Helicobacter pylori should undergo gastroscopy, and the gastroscopy report shows normal or chronic gastritis;

4. Patients aged 18-35 years (including 18) with positive Helicobacter pylori are not required to perform gastroscopy examination if there is no obvious clinical symptoms, or applying report of gastroscopy within 6 months showing normal or chronic gastritis.

Exclusion Criteria:

1. Gastroscopy report or previous medical history showed significant esophagus-gastric diseases, including gastric cancer, peptic ulcer, oesophagitis and esophageal erosion;

2. Patients with chronic diarrhea and chronic functional constipation;

3. Other systemic diseases, including cardiovascular diseases, lung diseases, liver diseases (transaminase index is more than 2 times higher than the normal value), kidney diseases (creatinine index is higher than the normal value) and other important organs with severe lesions, severe metabolic diseases (diabetes, thyroid diseases), malignant tumors, and severe immune system diseases;

4. Abnormal stool routine results: fecal occult blood (+) or white blood cells (+);

5. Patients with severe psychological or mental diseases;

6. Those with a history of drug abuse or alcohol abuse;

7. Those who are allergic to the drugs in this study;

8. Those who have received Helicobacter pylori eradication therapy;

9. Drugs which affect the intestinal flora(including antibacterial drugs, microecological preparations, intestinal mucosal protectors, Chinese patent medicines, etc.) have been used in the past 1 month or need to be used continuously for more than 1 week in the experiment.

10. Pregnant or lactating women;

11. Participating or after completing other clinical trials Less than 3 months;

12. Others who researchers consider unsuitable for inclusion.

Related Conditions & MeSH terms

• Helicobacter Pylori Eradication

Intervention

Drug:
• Bifidobacterium tetrad live bacteria tablet plus Helicobacter pylori quadruple eradication therapy
On day 1-14: Standard therapy: esomeprazole magnesium enteric-coated tablets, amoxicillin granules (A Mo Xian), furazolidone tablets, bismuth potassium citrate granules (Li Zhu De Le) are taken twice a day, once in the morning and once in the evening. Esomeprazole magnesium enteric-coated tablets and bismuth potassium citrate granules (Li Zhu De Le) should be taken 30min before meal; amoxicillin granules (A Mo Xian) and furazolidone tablets should be taken 30min after meal. Probiotic: Bifidobacterium tetrad live bacteria tablets should be taken at noon once a day (30 min after meal ), 9 tablets per time. On day 15-28: Probiotic: Bifidobacterium tetrad live bacteria tablets, taken at noon once a day (30min after meal), 9 tablets per time.
• Bifidobacterium tetrad live bacteria tablet placebo plus Helicobacter pylori quadruple eradication therapy
On day 1-14: Standard therapy: esomeprazole magnesium enteric-coated tablets, amoxicillin granules (A Mo Xian), furazolidone tablets, bismuth potassium citrate granules (Li Zhu De Le) are taken twice a day, once in the morning and once in the evening. Esomeprazole magnesium enteric-coated tablets and bismuth potassium citrate granules (Li Zhu De Le) should be taken 30min before meal; amoxicillin granules (A Mo Xian) and furazolidone tablets should be taken 30min after meal. Placebo: Bifidobacterium tetrad live bacteria tablet placebos should be taken at noon once a day ( 30 min after meal ), 9 tablets per time. On day 15-28: Placebo: Bifidobacterium tetrad live bacteria tablet placebos, taken at noon once a day (30min after meal), 9 tablets per time.

Locations

Country	Name	City	State
China	The First Affiliated Hospital of Nanchang University	Nanchang	Jiangxi
China	Xi'an Central Hospital	Xi'an	Shanxi

Sponsors (9)

Lead Sponsor	Collaborator
Hangzhou Grand Biologic Pharmaceutical, Inc.	Fifth Affiliated Hospital of Zhengzhou University, First Hospital of Shanxi Medical University, Nanjing First Hospital, Nanjing Medical University, Renmin Hospital of Wuhan University, The First Affiliated Hospital of Nanchang University, The First People's Hospital of Yunnan, Xi'an Central Hospital, Zhejiang Provincial Hospital of TCM

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	the total incidence rate of digestive tract related adverse reactions	The patient diary cards (including Bristol stool classification, diarrhea, constipation, abdominal pain, abdominal distension, belching, nausea, vomiting, loss of appetite and changes in taste) are filled in daily from the -14th day to 28th day. The above contents are recorded weekly from the 29th to182th day. to calculate the total incidence rate of digestive tract related adverse reactions mentioned above	baseline, 28 days, 182days
Secondary	the incidence rate of various digestive tract related symptoms	to calculate incidence rate of various digestive tract related symptoms including diarrhea, constipation, and other symptoms mentioned above	baseline, 28 days, 182days
Secondary	duration of various digestive tract related symptoms	to calculate duration of various digestive tract related symptoms including diarrhea, constipation, and other symptoms mentioned above	baseline, 28 days, 182days
Secondary	stool frequency	to evaluate the defecation frequency of diarrhea and constipation	baseline, 28 days, 182days
Secondary	changes in intestinal flora	to evaluate the changes of intestinal flora during the clinical study period	baseline, 14 days, 28 days, 70 days, 182days
Secondary	changes in gastric flora	20 patients are enrolled in the experiment group and control group respectively. Mucosal samples (one gastric antrum and one gastric body) are taken by gastroscopy before treatment. Gastroscope was reexamined 6 weeks after probiotics or placebo withdrawal (the 70th day), and mucosal samples (one gastric antrum and one gastric body) are taken.	baseline, 70 days
Secondary	Helicobacter pylori eradication rate	to evaluate the results of 13C-urea breath test	70 days
Secondary	adverse events	Adverse events are assessed during the clinical study period.	28 days,182 days